Shanghai Turtle Technology Co., Ltd, a leading Polymerase Chain Reaction (PCR) specialist in China, has entered into a strategic partnership with Shanghai Focusgen Biotech Co., Ltd, a company specializing in tumor liquid biopsy devices. This collaboration aims to accelerate advancements in the field of tumor liquid biopsies.
Focusgen Biotech’s flagship product, NextCTC, is a third-generation circulating tumor cells (CTCs) capture device that operates independently of antibodies. It features a fully automatic microscopic imaging scanning system, integrating nanofluidic technology with artificial intelligence (AI) recognition algorithms. This innovative system enables efficient and non-destructive capture and intelligent identification of circulating tumor cells, making it suitable for a range of subsequent experimental applications, including PCR, FISH, next-generation sequencing, single-cell sequencing, cell culture, and drug sensitivity testing.- Flcube.com
